Objective: Adults with severe GH de®ciency (GHD) need recombinant human growth hormone (rhGH) replacement to restore body composition, structure functions and metabolic abnormalities. The optimal rhGH dose for replacement has been progressively reduced to avoid side effects. The aim of the present study was to de®ne the minimal rhGH dose able to increase both IGF-I and IGF binding protein (BP)-3 levels in GHD and to verify the possible change in GH sensitivity. Design and patients: To this goal, we studied the effect of 4-day treatment with 3 rhGH doses (1.25, 2.5 and 5.0 mg/kg/day) on IGF-I and IGFBP-3 levels in 25 panhypopituitary adults with severe GHD (12 males and 13 females, age: 44X5^3X0 years, body mass index (BMI): 27X0^0X9 kgam 2 ) and 21 normal young adult volunteers (NV, 12 males and 9 females, age: 30X5^2X0 years, BMI: 20X8^0X5 kgam 2 ). Results: Basal IGF-I and IGFBP-3 levels in GHD were lower P , 0X001 than in NV. In NV the 1.25 mg/kg dose of rhGH did not modify IGF-I levels. The dose of 2.5 mg/kg rhGH signi®cantly increased IGF-I levels in men P , 0X001 but not in women, while the 5.0 mg/kg dose increased IGF-I levels in both sexes P , 0X001X IGFBP-3 levels were not modi®ed by any of the administered rhGH doses. In GHD patients, all rhGH doses increased IGF-I levels 12 h after both the ®rst P , 0X01 and the fourth rhGH dose P , 0X001X At the end of treatment percentage increases in IGF-I were higher P , 0X001 in GHD patients than in NV. In contrast with NV, in GHD patients the IGF-I response to short-term stimulation with rhGH was independent of gender. Moreover, GHD patients showed increases in IGFBP-3 after the fourth administration of both 2.5 and 5.0 mg/kg rhGH.
Introduction
The activity of the growth hormone/insulin-like growth factor-I (GH/IGF-I) axis has a major role in promoting growth, but also plays a key role in protein, glucose and lipid metabolism, in¯uencing body composition and structure function (1) . In adulthood, the metabolic actions of the GH/IGF-I axis take place at secretory levels which are markedly lower than those needed to promote growth (2) . IGF-I and IGF binding protein-3 (IGFBP-3) levels re¯ect the GH status (3), although IGF-I synthesis and release are also under important regulation by nutrition (4) .
IGF-I concentrations have been shown to be positively related to GH secretion in normal, acromegalic, and GH de®cient subjects and IGF-I measurement is widely used to assess disease activity in acromegaly (1) as well as to screen patients with suspected GH de®ciency (GHD) (1, 3) . Although the reliability of the IGF-I measurement for the diagnosis of GHD in adults has been questioned by many authors (5±8), there is agreement that it is the best parameter for monitoring the appropriate recombinant human growth hormone (rhGH) replacement therapy (9±11).
Adults with severe GHD show alterations in body composition, structure function and metabolism that are reversed by rhGH replacement treatment (9, 11± 18) . The rhGH dose for replacement therapy in adults with severe GHD has been progressively reduced to minimise side effects (10, 11, 15, 19, 20) . As alluded to before, IGF-I is the best biochemical marker for monitoring GH replacement and IGF-I values should be kept in the age-related normal range (9, 11) .
The aim of the present study was to de®ne the minimal rhGH dose able to increase IGF-I and IGFBP-3 levels in GH de®ciency and to verify the possible change in GH sensitivity. To this goal, we studied the effects of 4-day treatments with 3 low rhGH doses (1.25, 2.5 and 5.0 mg/kg/day) on IGF-I and IGFBP-3 levels in adults with severe GHD. These results were compared with those recorded in normal subjects in whom we have previously shown that IGF-I and IGFBP-3 responses to rhGH are dose-and sex-dependent (21) .
Subjects and methods
Twenty-®ve panhypopituitary adults with severe GH de®ciency (GHD, 12 males and 13 females, age: 44X53 X0 years, body mass index (BMI): 27X0^0X9kgam 2 ) were studied. Seventeen acquired panhypopituitarism after pituitary surgery or radiotherapy. All patients were on optimized replacement therapy other than GH for at least three months. As controls, 21 normal young adult volunteers (NV, 12 males and 9 females, age: 30X5^2X0 years, BMI: 20X8^0X5 kgam 2 ) were studied. None of the female volunteers received hormonal contraception and the study was performed in the early follicular phase. An independent Ethics Committee approved the study and all subjects gave informed consent to enter the study.
Severe GHD has been demonstrated in all patients by showing a GH peak ,3 mg/l after an insulin tolerance test (6, 11) and/or ,9 mg/l after GH releasing hormone (GHRH)+arginine test (11, 22) .
GHD patients and NV underwent 3 treatments with rhGH at doses of 1.25 mg/kg/day (n 14 and 21 respectively), 2.5 mg/kg/day (n 15 and 21 respectively) or 5 mg/kg/day (n 14 and 21 respectively). The rhGH doses (Norditropin; Novo-Nordisk, Copenhagen, Denmark and Genotropin; Pharmacia PH, Stockholm, Sweden; vials 4 IU 1X33 mg in 1 ml) were given subcutaneously every evening at 2100 h for 4 days. Tests were performed in random order at least one month apart. Blood samples for IGF-I, IGFBP-3, insulin and glucose levels were drawn basally and 12 h after the ®rst and the last rhGH administration (i.e. 84 h after the ®rst rhGH administration).
Serum IGF-I (mg/l) was measured in duplicate by RIA (Nicholls Institute Diagnostic, San Juan Capistrano, CA, USA). The sensitivity of the assay was 0.25 mg/l. The inter-and intra-assay coef®cients of variation were 5.2±8.4% and 2.4±3.0% respectively. Serum IGFBP-3 (mg/l) was measured in duplicate by RIA (Nicholls Institute Diagnostic). The sensitivity of the assay was 0.25 ng/ml. The inter-and intra-assay coef®cients of variation were 5.3±6.3% and 3.4±8.0% respectively. Serum insulin (mU/l) was measured in duplicate by IRMA (Sorin, Saluggia, Italy). The sensitivity of the assay was 2.5 mU/l. The inter-and intra-assay coef®cients of variation were 6.5±15.0% and 4.5± 13.4% respectively. Plasma glucose (mg/dl) was measured by the glucose-oxidase colorimetric method (Menarini Diagnostics, Firenze, Italy).
Data are expressed as means^S.E.M. of absolute and percentage changes. The statistical analysis of the data was carried out by paired and unpaired Student's t-test and ANOVA where appropriate.
Results

Normal volunteers (NV)
Mean basal IGF-I and IGFBP-3 levels were 212X15
X6 mgal and 2X9^0X1 mgal respectively and did not differ signi®cantly among various testing sessions.
The dose of 1.25 mg/kg rhGH failed to modify IGF-I levels at any time, while these were signi®cantly increased 12 h after the ®rst and the fourth administration of 2.5 mg/kg rhGH 220X9^12X8 and 242X9^13X4Y respectively, vs basal 205X3^14X8 mgal; P , 0X001 and 5.0 mg/kg rhGH 272X2^16X1 and 301X7^17X6Y respectively, vs basal 230X4^16X1 mgal; P , 0X001 showing a clear dose±response relationship P , 0X001 ( Fig. 1 and see also Fig. 3 ). When the data were examined by gender, the dose of 2.5 mg/kg rhGH was found signi®cantly to stimulate IGF-I levels in men P , 0X001 but not in women ( Table 1) .
None of the rhGH doses (1.25, 2.5 and 5.0 mg/kg) effected a change in IGFBP-3 levels (Fig. 2) . Glucose and insulin levels were not modi®ed at any time (data not reported). 
Patients with GH deficiency (GHD)
Mean basal IGF-I and IGFBP-3 levels (64X4^8X7 mgal and 1X6^0X2 mgal respectively) in GHD patients did not differ signi®cantly among various testing sessions and were clearly lower than those in NV P , 0X001X All rhGH doses (1.25, 2.5 and 5.0 mg/kg) increased IGF-I levels 12 h after both the ®rst 105X0^11X7 vs 72X2^11X6Y 91X0^16X4 vs 63X5^11X0 and 75X21 1X0 vs 52X1^10X5 mgal respectively, P , 0X01 and the fourth 130X2^15X3Y 122X5^23X5 and 112X81 5X0 mgal respectively, P , 0X001 rhGH dose, showing no dose±response relationship (P not signi®cant) ( Fig. 1 and see also Fig. 3 ). At the end of treatment, the delta IGF-I percentage increases were clearly higher P , 0X001 in GHD patients than in NV in response to all rhGH doses ( Fig. 3 and Table 1 ).
In contrast with NV, no gender-related difference was found in the IGF-I response to rhGH in GHD patients. In fact, even the lowest rhGH dose, i.e. 1.25 mg/kg, elicited the same increase in IGF-I levels in GHD patients of both sexes (P , 0X001 vs baseline) ( Table 1) .
GHD patients also showed a signi®cant increase in IGFBP-3 after the fourth administration of both 2.5 and 5.0 mg/kg rhGH 2X4^0X2 vs 1X8^0X4 and 2X00
X2 vs 1X3^0X3 mgal respectively, P , 0X05 (Fig. 2 ).
Insulin and glucose levels were not modi®ed by any rhGH dose (data not reported).
Discussion
The results of the present study demonstrate that, at least after very short-term treatment, the minimal rhGH dose able to increase IGF-I or IGFBP-3 levels is lower in GHD adults than in normal subjects, suggesting an enhanced GH sensitivity. Moreover, the mean IGF-I percentage increase after each rhGH dose administered was higher in GHD patients than in normal subjects.
The stimulatory effect of low rhGH doses (ranging from 2.5 to 5.0 mg/kg/day) on IGF-I levels in GHD adults has already been studied by other authors (10, 23) although it has never been compared with data in normal subjects. Our study shows that a rhGH dose as low as 1.25 mg/kg/day (that is about 0.00375 IU/kg/day) is able to stimulate IGF-I levels in severe GHD patients, although after very short-term treatment. This evidence does not imply that this dose is effective for optimal replacement; in fact, it has already been shown that the IGF-I response to rhGH is not strictly associated with protein anabolism (23) and clinical bene®t (11, Figure 1 Effect of 4-day treatment with 3 rhGH doses (O, 1.25 mg/kg/day; X, 2.5 mg/kg/day; B, 5.0 mg/kg/day) on IGF-I levels (mean^S.E.) in 21 normal volunteers and 25 patients with severe GH de®ciency. *P , 0X01Y **P , 0X001 vs baseline; 5 rhGH administration.
Enhanced GH sensitivity in GHD adults 20). Treatment did not show a dose±response relationship at variance with that recorded in normal subjects. This result agrees with the ®nding of a similar increase in IGF-I levels following a one-week treatment with either 2.0 or 3.3 mg/kg/day rhGH in hypopituitary adults (23) . Interestingly, in those subjects a dose± response relationship became apparent only after one month of treatment.
Thus, it is apparent from the present study that, at least at the beginning of GH replacement, patients with severe GHD show an enhanced GH sensitivity. It has been clearly shown that the GH-receptor (GH-R) status is regulated by GH itself (24) . In GHD, many authors reporting contrasting results (19, 24±29) have studied GH binding protein (GHBP) levels as a marker of GH-R status. The existence of peripheral hypersensitivity to GH in patients with severe GHD (present data) agree with data by Roelen et al. (27) and Florkowski et al. (28) reporting increased GHBP levels in severe GHD during rhGH replacement. On the other hand, other authors have found that GHBP levels are reduced or unchanged (19, 24±26, 29) .
In contrast with normal subjects, our results show that there is no gender-related difference in the IGF-I response to rhGH in GHD patients. This ®nding is noteworthy considering that hypopituitary women need a higher rhGH dose than men for optimal IGF-I response and clinical bene®t (19, 30, 31) , according to the inhibitory in¯uence of estradiol on IGF-I synthesis and release (32, 33) . However, our hypopituitary women were on transdermal estradiol replacement and there is already evidence that the negative in¯uence of estradiol on IGF-I synthesis and release depends on the method of administration as well as on the estrogenic dose in both normal and GHD patients (34, 35) . On the other hand, in the present experimental conditions, the existence of an enhanced GH sensitivity in our patients may mask the evidence of a gender-related difference in the IGF-I response to rhGH with the GH doses employed. To demonstrate a genderrelated difference, testing with a rhGH dose lower than 1.25 mg/kg would be helpful. Moreover, the possibility has to be considered that the lack of a sex-related difference is limited to the ®rst days of treatment and that it could become apparent later on. We are now studying the long-term effect of 0.625, 1.25, 2.5 and 5.0 mg/kg/day rhGH doses in GHD patients of both sexes. Finally, the small number of patients studied limited the ®nding of a lack of a gender-related difference.
In agreement with other authors, our data further indicate that IGFBP-3 is a less sensitive marker of GH Figure 2 Effect of 4-day treatment with 3 rhGH doses (O, 1.25 mg/kg/day; X, 2.5 mg/kg/day; B, 5.0 mg/kg/day) on IGFBP-3 levels (mean^S.E.) in 21 normal volunteers and 25 patients with severe GH de®ciency. *P , 0X05 vs baseline; 5 rhGH administration.
status than is IGF-I (36, 37) and it is also less sensitive than IGF-I to rhGH stimulation (8, 10, 21) . In spite of this, GHD patients showed a signi®cant increase in IGFBP-3 levels with rhGH doses which were ineffective in normal subjects. As IGFBP-3 synthesis and release depend not only on GH but also on IGF-I (4, 38), the enhanced IGFBP-3 sensitivity in GHD patients could also depend on the higher increases in IGF-I, at variance with normal volunteers.
In conclusion, the present study demonstrates that the IGF-I and IGFBP-3 responses to very low doses of GH are enhanced in GHD compared with normal subjects, at least after very short-term treatment. This evidence suggests the existence of enhanced peripheral GH sensitivity in GH deprivation.
